

is a marked-up version of the changes made by the current amendment. The attached page is captioned "Version With Markings to Show Changes Made." Deletions are bracketed and additions are underlined and in bold. No new matter has been added.

Thus, applicants believe this Response places the subject application into compliance with the requirements of 37 C.F.R. 1.821-1.825. Applicants respectfully request that the substitute Sequence Listing be entered into the subject application.

DEPOSIT ACCOUNT

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 09/12/2002 By: A. A. Taylor

Arles A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

1406/50 AAT/JB/CPP/ptw/ajm



25297

PATENT TRADEMARK OFFICE

Enclosures:

- Version With Markings to Show Changes Made (4 pages)
- Substitute paper copy of Sequence Listing (6 pages)
- CRF Sequence Listing (diskette)
- Copy of Notification of Missing Requirements

"Express Mail" mailing number: EV155319817US  
Date of Deposit September 12, 2002  
I hereby certify that this paper and all papers and fees referred  
to herein are being deposited with the United States Postal  
Service "Express Mail Post Office to Addressee" service under  
7 C.F.R. 1.10 on the date indicated above and is addressed to the  
Commissioner for Patents, Washington, D.C. 20231  
Bonnie S. Sheridan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bornkamm et al. Group Art Unit: Not Assigned

Serial No.: 10/088,853 Examiner: Not Assigned

Filed: March 21, 2002 Docket No.: 1406/50

For: METHOD FOR IDENTIFYING MHC-RESTRICTED ANTIGENS

\*\*\*\*\*

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Deleted text is enclosed in brackets ([ ]). Text to be added is underlined  
and in bold typeface.

IN THE SPECIFICATION:

The paragraph beginning at page 9, line 9, has been amended as  
follows:

The 3' conserved regions of wild type influenza viruses have the following  
sequences:

influenza A: (5')-CCUGCUUUUGCU-3' (SEQ ID NO:1)

influenza B: (5')-NN(C/U)GCUUCUGCU-3' (SEQ ID NO:2)

influenza C: (5')-CCUGCUUCUGCU-3' (SEQ ID NO:3)

The paragraph beginning at page 9, line 16, has been amended as  
follows:

Optionally, there may be also made exchanges in the 5' conserved region of the  
 wild type consisting of 13 nucleotides, e.g. in positions 3 and 8 again with the  
 proviso that the inserted nucleotides form a base pair. The 5' conserved regions  
 of wild type influenza viruses have the following sequences:

influenza A: (5')-AGUAGAAACAAGG-3' (SEQ ID NO:4)

influenza B: (5')-AGUAG(A/U)ACCA(A/G)NN-3' (**SEQ ID NO:5**)

influenza C: (5')-AGCAGUAGCAAG(G/A)-3' (**SEQ ID NO:6**)

The paragraph beginning at page 9, line 27, has been amended as follows:

Preferably, those mutants of the influenza virus are used in the present invention wherein the alterations G3A and C8U may be made in the 3' conserved region. Most preferable influenza mutants are the influenza A mutants and particularly those mutants which additionally show the U5C exchange (the above-mentioned mutants are numbered starting from their 3' ends; counting from the 3' end is indicated by a line above the number such as G3A). Further preferred influenza mutants comprise the mutations G3C, U5C, and C8G (counted from the 3' end) in the 3' terminal nucleotide sequence resulting in the following 3' terminal nucleotide sequence:

(5')-CCUGGUUCUCCU-3' (**SEQ ID NO:7**)

The paragraph beginning at page 10, line 7, has been amended as follows:

Among the influenza viruses defined above those are particularly preferred which show the following 3' terminal nucleotide sequence:

(5')-CCUGGUUUCUACU-3' (**SEQ ID NO:8**)

The paragraph beginning at page 10, line 18, has been amended as follows:

The most preferred influenza promoter-up variants of the present invention have the following general structures:

influenza A (promoter-up variant '1104'):

5'-AGUAGAAACAAGGNNNU<sub>[5-6]</sub>UUUU...(880-2300 ntd)...N'N'N'CCUGUuuCUACU-3'

(SEQ ID NO:9)

(SEQ ID NO:11)

5'-AGUAGAAACAAGGNNNUUUUUU...(880-2300 ntd)...N'N'N'CCUGUuuCUACU-3'

(SEQ ID NO:10)

(SEQ ID NO:11)

influenza A (promoter-up variant '1920'):

5'-AGAAGAAUCAAGGNNNU<sub>[5-6]</sub>UUUU...(880-2300 ntd)...N'N'N'CCUGUuuCUACU-3'

(SEQ ID NO:12)

(SEQ ID NO:14)

5'-AGAAGAAUCAAGGNNNUUUUUU...(880-2300 ntd)...N'N'N'CCUGUuuCUACu-3'

(SEQ ID NO:13)

(SEQ ID NO:14)

influenza A (promoter-up variant '1948'):

5'-AGUAGAAACAAGGNNNU<sub>[5-6]</sub>UUUU...(880-2300 ntd)...N'N'N'CCUGGUUCUCCU-3'

(SEQ ID NO:15)

(SEQ ID NO:17)

5'-AGUAGAAACAAGGNNNUUUUUU...(880-2300 ntd)...N'N'N'CCUGGUUCUCCu-3'

(SEQ ID NO:16)

(SEQ ID NO:17)

influenza B:

5'-AGUAG(A/U)AAC(A/G)NNNNNU<sub>[5-6]</sub>UUUU...(880-2300 ntd)...N'N'N'N'(C/U)GUUUCUACU-3'

(SEQ ID NO:18)

(SEQ ID NO:20)

5'-AGUAG(A/U)AAC(A/G)NNNNNUUUUUU...(880-2300 ntd)...N'N'N'N'(C/U)GUUUCUACu-3'

(SEQ ID NO:19)

(SEQ ID NO:20)

influenza C:

5'-AGUAGUAACAAG(G/A)GU[5-6]UUUU...(880-2300 ntd)...CCCCUGUUUCUACU-3'

(SEQ ID NO:21)

(SEQ ID NO:23)

5'-AGUAGUAACAAG(G/A)GUUUUUU...(880-2300 ntd)...CCCCUGUUUCUACU-3'

(SEQ ID NO:22)

(SEQ ID NO:23)

Please delete the Sequence Listing as filed an insert in place thereof the Sequence Listing enclosed herewith.